• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦ EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Cardiology

Ambulatory rhythm monitoring detects heart block after transcatheter aortic valve replacement

byJames EnglandandAnees Daud
June 1, 2019
in Cardiology, Emergency
Reading Time: 2 mins read
Cerebral protection device effective in patients undergoing transcatheter aortic valve implantation
Share on FacebookShare on TwitterShare on LinkedIn

1. The routine use of ambulatory event monitoring (AEM) commonly detects high grade atrioventricular block (H-AVB) after discharge following Transcatheter Aortic Valve Replacement (TAVR).

2. The presence of a right bundle branch block (RBBB) is a specific but not sensitive predictor of H-AVB in patients following TAVR.

Evidence Rating Level: 2 (Good)

Study Rundown: Transcatheter Aortic Valve Replacement (TAVR) for management of aortic valve disease is preferred in patients who may be higher risk for surgical repair. The development of high grade AV block following TAVR is a common complication necessitating the implantation of a pacemaker in many patients. Though more commonly diagnosed in hospital, the streamlining of procedures and reduced recovery time has led to shorter admissions for TAVR and more patients may develop H-AVB at home following discharge. This study evaluated the utility of routine ambulatory event monitoring (AEM) following discharge after TAVR for the detection of H-AVB. The study found that development of delayed H-AVB was common, occurring in up to 10% of monitored patients. The presence of RBBB following TAVR was a specific, but not sensitive, finding in predicting the development of delayed H-AVB.

The main strength of this study was the recruitment of consecutive patients agreeing to long-term rhythm monitoring allowing for initial evaluation of risk of delayed H-AVB. The main limitations of the study included the small size, and lack of data on important procedural risk factors that may influence risk of AV block.

Click to read the study in JACC

RELATED REPORTS

Tarlatamab plus durvalumab improved survival versus durvalumab alone in extensive-stage small cell lung cancer, Amgen reports in interim phase 3 results

Sacituzumab tirumotecan improved overall survival versus platinum chemotherapy in company-reported final phase 3 results

Relevant Reading: The Electrocardiogram After Transcatheter Aortic Valve Replacement Determines the Risk for Post-Procedural High-Degree AV Block and the Need for Telemetry Monitoring

In-Depth [retrospective cohort]: This was a retrospective cohort study of patients undergoing TAVR at the University of Colorado Hospital between October 2016 and March 2018. Participants were excluded if they had pre-existing pacemarker or implanted cardioverter-defibrillator, or if they developed high grade AV block following TAVR prior to discharge from hospital. Ambulatory event monitoring for up to 30 days was performed in patients who consented.

The study included 150 consecutive patients, of whom 13 refused participation in the trial and 18 developed H-AVB prior to discharge. Of the 118 patients who underwent AEM following discharge, 12 (10%) developed H-AVB after a median of 6 days (range 3-24 days). The presence of a RBBB on electrocardiogram was 27% sensitive and 94% specific for predicting the development of delayed H-AVB.

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Previous Post

Increased number of daily steps linked with decreased mortality in older women

Next Post

Quick Take: Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART)

RelatedReports

An illustration showing human lungs, a tray with sampling devices, and a teal awareness ribbon, representing lung cancer diagnostics and lymph node sampling.
2MM Trial Briefs

Tarlatamab plus durvalumab improved survival versus durvalumab alone in extensive-stage small cell lung cancer, Amgen reports in interim phase 3 results

October 26, 2026
Illustration showing the lungs with a tumor, a vial representing medication, and surgical tools, indicating lung cancer treatment involving toripalimab.
2MM Trial Briefs

Sacituzumab tirumotecan improved overall survival versus platinum chemotherapy in company-reported final phase 3 results

October 25, 2026
An illustration of the pancreas, highlighting cancer cells related to pancreatic cancer and molecular structures, indicating targeted research in oncology.
2MM Trial Briefs

Camupepimut did not improve disease-free survival versus observation in pancreatic cancer in the randomized phase 2 AMPLIFY-7P trial

October 25, 2026
An older woman looks thoughtfully to the side, with dumbbells, running shoes, and a bottle of supplements nearby, suggesting themes of exercise and health in geriatrics.
Chronic Disease

An electronic health record tool for exercise prescription may reduce fall rate among older adults

October 24, 2026
Next Post
No difference in mortality for intensive versus standard reduction in blood pressure in intracerebral hemorrhage: The ATACH-2 trial

Quick Take: Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART)

#VisualAbstract: Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke

#VisualAbstract: Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke

High rates of over-diagnosis of pulmonary embolism by CT angiography

Quick Take: Treatment and Long-Term Clinical Outcomes of Incidental Pulmonary Embolism in Patients With Cancer

✦ EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

NPI Lookup · Free

Look up any US clinician

Search by name or NPI number, live from the CMS NPI Registry.

  • OIG exclusion check
  • Licenses and specialties
  • No account needed
Open NPI Lookup →

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Tarlatamab plus durvalumab improved survival versus durvalumab alone in extensive-stage small cell lung cancer, Amgen reports in interim phase 3 results
  • Sacituzumab tirumotecan improved overall survival versus platinum chemotherapy in company-reported final phase 3 results
  • Camupepimut did not improve disease-free survival versus observation in pancreatic cancer in the randomized phase 2 AMPLIFY-7P trial
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓NPI watchlist + bulk NPI verification

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.